NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 4.4% and is now trading at $485.19. View which stocks have been mosted impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings results on Thursday, February, 6th. The biopharmaceutical company reported $7.50 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $6.03 by $1.47. The biopharmaceutical company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. The firm's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the previous year, the company posted $6.84 EPS. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its board has approved a share buyback program on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy up to 2.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its stock is undervalued.

24 Wall Street analysts have issued 12-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $550.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $460.13 in the next twelve months. This suggests that the stock has a possible downside of 5.2%. View analysts' price targets for Regeneron Pharmaceuticals.

Media stories about REGN stock have trended somewhat negative on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutRegeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 2,558,900 shares, a decline of 11.1% from the February 27th total of 2,880,000 shares. Based on an average trading volume of 1,294,900 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.1% of the shares of the stock are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), Biogen (BIIB), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Alphabet (GOOG), Micron Technology (MU) and Broadcom (AVGO).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $485.19.

Regeneron Pharmaceuticals has a market capitalization of $53.38 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe. View additional information about Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]